Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00313300 · ClinicalTrials.gov registry record · Phase 2
Safety Study of Apixaban in Recent Acute Coronary Syndrome
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,741
- Enrollment target
NCT00313300 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 1,741 participants.
The verdict
NCT00313300, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,741 participants
- Enrollment target
Study Summary
The purpose of this clinical research study is to determine whether apixaban will be safe in people who have recently had unstable angina or a heart attack.
Interventions
- DRUG Placebo
- DRUG Apixaban
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,741 participants |
| Start Date | 2006-05 |
| Est. Completion | 2008-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00313300
The ClinicalTrials.gov registry entry for NCT00313300 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1,741 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00313300 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00313300 about?
NCT00313300 is a clinical study titled "Safety Study of Apixaban in Recent Acute Coronary Syndrome". The purpose of this clinical research study is to determine whether apixaban will be safe in people who have recently had unstable angina or a heart attack.
What is the current status of trial NCT00313300?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,741 participants. The study started on 2006-05. Estimated completion is 2008-05.
What interventions are being tested in trial NCT00313300?
The interventions under investigation include: Placebo (DRUG), Apixaban (DRUG).
Who is sponsoring clinical trial NCT00313300?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.